Salbutamol sulfate, ipratropium bromide.
Each 2.5-mL nebule contains salbutamol sulfate 2.5 mg and ipratropium bromide 500 mcg.
Multivent also contain water for injections as excipient.
Salbutamol sulfate and ipratropium bromide is an anticholinergic (parasympatholytic) agent which acts by inhibiting vagally-mediated reflexes by antagonizing the action of acetylcholine, the transmitter agent released from the vagus nerve. Salbutamol is a relatively selective β2-adrenergic agonist whose activation leads to the increase in the intracellular adenyl cyclase, the enzyme which catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3'5'-adenosine monophosphate (cAMP).
Adjunct treatment to anti-inflammatory therapy and bronchodilators in asthma to prevent exacerbations; maintenance treatment of chronic obstructive pulmonary disease (COPD) including chronic bronchitis and emphysema.
1 nebule 3-4 times a day. The dosage should be adapted to the individual requirements of the patient.
Symptoms: The effects of overdosage are expected to be primarily related to salbutamol because acute overdosage with ipratropium bromide is unlikely as it is not well absorbed systematically after inhalation or oral administration. Hypokalemia may occur following overdosage. Serum potassium levels should be monitored. Manifestations of overdosage with salbutamol may include angina pain, hypertension, hypokalemia and tachycardia.
Treatment: The preferred antidote for overdosage with salbutamol is a cardioselective β-blocking agent but due care and attention should be taken while administering these drugs in patients with a history of bronchospasm.
Hypersensitivity to atropine and its derivatives or to any of the component of Multivent, soya lecithin or related food products eg, soybean and peanut.
Tremor, nervousness, tachycardia, dizziness, headache, hypokalemia, dry mouth, throat irritation, urinary retention, nausea and arrhythmia may occur. Allergic-type and anaphylactic reactions have been reported in some cases. As with other bronchodilators, in some cases cough, and in very rare instances, paradoxical bronchoconstriction have been observed.
The combination has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines and steroids, commonly used in the treatment of asthma and COPD, without adverse reactions. Caution is advised when salbutamol sulfate and ipratropium bromide is co-administered with other anticholinergic drugs, β-blockers, α-adrenergic agents, diuretics, monoamine oxidase inhibitors or tricyclic antidepressants.
Store at temperatures not exceeding 30°C.
R03AL02 - salbutamol and ipratropium bromide ; Belongs to the class of combination of adrenergics with anticholinergics, that may also include a corticosteroid. Used in the treatment of obstructive airway diseases.
Multivent nebules
35 × 1's
Sign Out
Continue with Google
Sign up with email
Already a member?
Sign in
